

Lyme Autoimmune

Explore the Link Between Infections and Autoimmunity

Dealing with joint pain, fatigue, brain fog, numbness, or recurring symptoms that don't resolve? Your immune system may react to chronic infections or be confused by cross-reactive triggers. The Lyme & Autoimmune Panel provides insights into possible root causes by analyzing immune responses to Lyme-related pathogens and self-tissue antigens.

It also identifies markers of autoimmunity, molecular mimicry, and neuroinflammation—factors that can silently drive chronic symptoms, neurological issues, and systemic dysfunction. If you've been searching for answers without clarity, this test offers a deeper look at how infections may impact your immune system and overall health.

With science-backed insights and targeted recommendations, your healthcare provider can create a personalized plan to manage immune triggers, support recovery, and help bring the immune system back into balance.

How It Works

The Lyme & Autoimmune panel is a simple blood test that comprehensively views immune system activity related to chronic infections and autoimmune reactivity. It analyzes antibody responses to multiple species of *Borrelia* and other vector-borne pathogens, alongside autoantibodies to the nervous system, connective tissue, and other self-antigens. This test goes beyond standard Lyme panels to detect early signs of immune dysfunction, molecular mimicry, and inflammation contributing to joint pain, fatigue, neurological symptoms, or unexplained systemic issues. With clear visuals and personalized insights, your provider can create a targeted plan to reduce immune triggers and support long-term recovery.


Why Choose the Lyme Autoimmune Test?

- **Shows Responses to Lyme Disease:** Identifies autoimmune responses linked to Lyme disease and co-infections such as *Babesia*, *Bartonella*, and *Ehrlichia*, providing valuable insights into chronic health issues caused by tickborne infections.
- **Measuring Markers for Early Signs:** Measures antibodies and immune markers that reveal early signs of Lyme disease, enabling timely intervention and reducing the risk of long-term complications like neuroborreliosis and chronic fatigue syndrome.
- **Detecting Early Lyme Autoimmune Activity:** Early detection of Lyme-related autoimmune activity allows for targeted treatment to address symptoms and prevent disease progression.
- **Displays Personalized Plan:** Helps healthcare providers create personalized treatment plans that address Lyme disease and co-infections, improving recovery times and reducing the impact on overall health.



Key Markers Include:

- **Borrelia IgG & IgM (Lyme Disease):** Detects immune responses to multiple *Borrelia* species, including *B. burgdorferi*, *B. afzelii*, and *B. garinii*—key pathogens associated with Lyme disease.
- **Babesia, Bartonella, Ehrlichia, Rickettsia (Co-Infections):** Identifies tick-borne infections that may co-occur with Lyme and contribute to persistent fatigue, joint pain, and neurological symptoms.
- **Myelin Basic Protein, Collagen, & Endothelial Antigens (Autoimmunity):** Detects antibodies against self-tissues linked to joint inflammation, nerve damage, and vascular reactivity.
- **S100B & GFAP (Neuroinflammation):** Evaluates markers of blood-brain barrier integrity and glial cell activation, associated with cognitive changes, mood symptoms, and CNS involvement.
- **Molecular Mimicry Antigens (Cross-Reactivity):** Screens for immune responses to microbial and self-antigens that mimic each other—an early signal of infection-triggered autoimmunity.
- **Pathogen-Triggered Immune Complexes:** Measures antibody complexes that suggest unresolved immune activation, contributing to systemic inflammation and immune dysregulation.



The Lyme & Autoimmune panel analyzes immune responses to infections, self-tissue antigens, and neuroinflammatory markers to uncover potential root causes of joint pain, fatigue, brain fog, numbness, and recurring symptoms. It identifies immune patterns linked to Lyme disease, co-infections, and autoimmune reactivity—key drivers of chronic symptoms and systemic dysfunction.

Who Should Take This Test?

- **Chronic Symptoms That Don't Resolve?** Joint pain, fatigue, brain fog, or numbness may signal immune dysregulation or hidden infections. This test helps uncover what's driving your symptoms.
- **Treated for Lyme but Still Unwell?** Persistent symptoms after treatment may reflect immune activation or autoimmunity—this panel helps clarify next steps.
- **Neurological Changes Without Clear Cause?** Tingling, cognitive shifts, or light sensitivity can stem from neuroinflammation—this test helps identify immune system involvement.
- **Unexplained Flare-Ups or Autoimmune Concerns?** Detect cross-reactive antibodies and early autoimmune patterns that standard tests may miss.
- **Focused on Long-Term Immune Health?** For patients seeking clarity and prevention, this panel reveals underlying immune activity before disease fully develops.

Take the First Step Towards Better Health

If you're dealing with joint pain, fatigue, brain fog, or unexplained neurological symptoms, your immune system could be the missing link. The Lyme & Autoimmune panel delivers clear answers and personalized insights to help identify immune triggers and guide targeted care. Talk to your healthcare provider today and take the next step toward better clarity, resilience, and long-term health.

Limitations

Please note the information provided by Vibrant Wellness is intended solely for research and informational purposes to help inform lifestyle choices aimed at potential risk mitigation. The information is not intended to be used by the patient for any diagnostic purpose and is not a substitute for medical advice by a healthcare practitioner. Please consult a licensed healthcare practitioner for any questions regarding diagnosis, prevention, or treatment of any disease or health assessment.

The test is not available in NY State.

Regulatory Disclaimer

Please note the information provided by Vibrant Wellness is intended solely for research and informational purposes to help inform lifestyle choices aimed at potential risk mitigation. The tests were developed, and their performance characteristics were determined by Vibrant America and Vibrant Genomics. They have not been cleared or approved by US Food and Drug Administration. The laboratory is certified under the Clinical Laboratory Improvements Amendments (CLIA) as qualified to perform high complexity testing. The laboratory is also in compliance with College of American Pathologists (CAP) regulations and New York State Department of Health (NYSDOH) regulations.